Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases.
about
Pharmacokinetics of intravenous immunoglobulin: a systematic review.Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiencySafety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects.A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.Surveillance study on the tolerability and safety of Flebogamma® DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients.Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.Improved IgG3 levels and reduced infection rate in a woman with CVID switched from intravenous to subcutaneous immunoglobulin therapy.
P2860
Q33371277-7D6DF9B8-BF20-4AE1-A94D-83B2A91EB46BQ33396204-C261F4A2-EB69-4489-93A1-7ADD73B862BCQ34196146-522E2F43-07D7-4352-9C71-774A02A9179CQ35566525-976DBF74-24FA-47FE-AB2D-5734D2F889ADQ36074636-750261FE-3200-4B22-B6D8-C2D455BEDD4BQ36196688-824BF342-968C-4D72-8E02-CEA590D6E293Q38111424-E9CB8C25-EE68-4CA3-9643-B0FB21FA34B8Q38188031-16F8DE89-E45A-4EEA-A195-B93AC24C04F4Q40179168-7AADB85A-981C-48CB-86C5-358DB9E408E0Q40343724-D0C0E3E5-D0C7-4EDE-99BA-56A8A6B8CF7FQ40356366-4D3E0C39-93CD-4535-9546-4DB1ABCF2AF8Q40639960-A68E87E9-D141-4F4C-B7EE-A26ABEB09F91Q42183204-442F9E4F-ECD2-45F2-AA33-371AA750B14CQ42694622-73C3304A-A532-4DA1-A72F-F534BF3307D1Q45257638-A46FD201-77BC-44CC-AE0A-66C19978C339
P2860
Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Safety, efficacy, and pharmaco ...... ary immunodeficiency diseases.
@en
Safety, efficacy, and pharmaco ...... ary immunodeficiency diseases.
@nl
type
label
Safety, efficacy, and pharmaco ...... ary immunodeficiency diseases.
@en
Safety, efficacy, and pharmaco ...... ary immunodeficiency diseases.
@nl
prefLabel
Safety, efficacy, and pharmaco ...... ary immunodeficiency diseases.
@en
Safety, efficacy, and pharmaco ...... ary immunodeficiency diseases.
@nl
P2093
P1476
Safety, efficacy, and pharmaco ...... ary immunodeficiency diseases.
@en
P2093
Flebogamma 5% Investigators
Melvin Berger
Paul J Pinciaro
P304
P356
10.1023/B:JOCI.0000029108.18995.61
P577
2004-07-01T00:00:00Z
P6179
1045942704